- Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference
- Amarin Reports First Quarter 2024 Business Update and Financial Results
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event
- Amarin Announces Results of Annual General Meeting of Shareholders
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo
- Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
More ▼
Key statistics
As of last trade, Amarin Corporation PLC (EH3A:MUN) traded at 0.765, 25.41% above the 52 week low of 0.61 set on Nov 03, 2023.
52-week range
Open | 0.765 |
---|---|
High | 0.765 |
Low | 0.765 |
Bid | 0.785 |
Offer | 0.815 |
Previous close | 0.79 |
Average volume | 116.89 |
---|---|
Shares outstanding | 410.87m |
Free float | 381.31m |
P/E (TTM) | -- |
Market cap | 346.90m USD |
EPS (TTM) | -0.1288 USD |
Data delayed at least 15 minutes, as of May 24 2024 07:00 BST.
More ▼